BioNTech Stock Falls After Cancer Trial Misses Key Endpoint

3-line summary

• BioNTech said a mid-to-late-stage trial of its experimental mRNA cancer therapy BNT113, combined with pembrolizumab as a first-line treatment for HPV-associated advanced head and neck cancer, failed to meet its first primary endpoint of improving progression-free survival compared with standard treatment alone, according to Investing.com. Nasdaq-listed BNTX shares fell 5% Tuesday following the announcement.
• An independent data monitoring committee recommended the study continue to assess its second primary endpoint, overall survival; the trial will be considered a success if overall survival improves. BioNTech said it will not access ongoing data to avoid bias.

This summary is our own processing of the source article; see the source link below for full context.